stockrow
Friday 6 November 2026
Export GSK’s income statement to Excel — free account
GSK PLC Sponsored ADR
GSK Healthcare Drug Manufacturers General
GSK PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $43.1 billion, up 7.44% from fiscal 2024.
- Revenue
- +3.75%
- EPS
- −14.7%
- Free cash flow
- +62.4%
- Total debt
- +33.2%
Quarter to September 2026, against a year earlier
50.34
0.07
−0.14%
Follow GSK
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
13.22 | 14.26 | 16.33 | 15.99 |
P/S ratio |
2.31 | 2.53 | 2.36 | 2.15 | |
P/FCF ratio |
15.39 | 16.97 | 13.76 | 10.94 | |
P/Operating CF |
34.92 | 72.20 | 29.19 | 25.49 | |
P/B ratio |
4.72 | 4.73 | 4.56 | 3.91 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
2.74 | 3.01 | 2.82 | 2.77 | |
EV/EBITDA |
8.74 | 9.85 | 9.80 | 10.19 | |
EV/Operating CF |
11.56 | 12.81 | 11.38 | 10.56 | |
EV/FCF |
18.29 | 20.17 | 16.40 | 14.08 | |
Quick Ratio |
0.53 | 0.51 | 0.52 | 0.56 | |
Current Ratio |
0.82 | 0.79 | 0.82 | 0.86 | |
Net Debt/EBITDA |
21.84 | 5.63 | 5.43 | 7.10 | |
Debt/Assets |
28.99% | 30.31% | 29.54% | 33.06% | |
Debt/Equity |
1.11 | 1.09 | 1.06 | 1.29 | |
Asset Turnover |
0.55 | 0.54 | 0.55 | 0.50 | |
Operating CF/Net income |
3.34 | 0.66 | 6.17 | 1.83 | |
Capex/Depreciation |
2.08 | (0.76) | (0.16) | (0.68) | |
Interest Coverage |
5.90 | 13.73 | 2.64 | 9.71 | |
Research and Development Expense of Revenue |
27.15% | 22.18% | 41.22% | 22.31% | |
Selling, General and Administrative Expense of Revenue |
30.64% | 27.78% | 26.19% | 26.81% | |
Intangible Assets out of Total Assets |
0.39 | 0.40 | 0.39 | 0.47 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Graham Net Nets |
(0.37) | (0.34) | (0.34) | (0.49) | |
Graham Number |
29.45 | 31.88 | 28.80 | 28.90 | |
Earnings Yield |
7.57% | 7.01% | 6.12% | 6.25% | |
Free Cash Flow Yield |
6.50% | 5.89% | 7.27% | 9.14% | |
Revenue per Share |
5.64 | 5.11 | 5.62 | 5.96 | |
Operating CF per Share |
1.40 | 0.76 | 1.80 | 1.89 | |
Capex per Share |
(0.63) | (0.24) | (0.24) | (0.36) | |
Free Cash Flow per Share |
0.77 | 0.53 | 1.56 | 1.53 | |
Cash per Share |
2.30 | 2.36 | 2.14 | 2.06 | |
Shareholders Equity per Share |
10.39 | 11.67 | 11.49 | 12.32 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
10.39 | 11.67 | 11.49 | 12.32 | |
Free Cash Flow |
1,567.56 | 1,060.48 | 3,126.87 | 3,075.11 | |
Working Capital |
(5,117.87) | (6,290.13) | (5,334.85) | (3,799.34) | |
Capital Expenditures |
(1,276.93) | (477.01) | (477.22) | (713.44) | |
Net Current Asset Value |
(36,464.69) | (37,306.88) | (36,239.39) | (47,665.94) | |
EV/EBIT |
11.29 | 12.26 | 14.41 | 15.41 | |
Capex to Sales |
0.11 | 0.05 | 0.04 | 0.06 | |
Price to Operating Income |
9.50 | 10.32 | 12.09 | 11.97 | |
| Other line items | |||||
Average Receivables |
9,796.20 | 10,071.31 | 10,558.12 | 11,329.12 | |
Average Payables |
19,939.76 | 19,198.29 | 19,521.00 | 21,076.58 | |
Average Inventory |
7,528.20 | 7,926.78 | 8,270.42 | 8,359.66 | |
Average Assets |
78,292.04 | 80,586.97 | 81,001.78 | 89,553.41 | |
Average Common Equity |
18,881.89 | 20,336.68 | 21,112.23 | 22,963.59 |
Columns are period end dates · fundamentals updated 2 Nov 2026